Biography
I am a board-certified medical oncologist focusing on gastrointestinal malignancies, with a special interest in biliary tract cancers and cancers of the upper GI tract. My clinical and research interests include investigator initiated clinical trials in hepatobiliary cancers, evaluating resistance mechanisms to therapeutic agents.
Positions
Roswell Park Comprehensive Cancer Center
- Assistant Professor of Oncology
- Department of Medicine
Background
Education and Training
- 2005-2011 - MD — Stanley Medical College, Chennai, India
Residency
- 2014-2017 - Internal Medicine, University of Alabama at Birmingham School of Medicine, Montgomery Internal Medicine Residency Program, Montgomery, AL
Fellowship
- 2017-2020 - Hematology and Medical Oncology, Henry Ford Health System/Wayne State University, Detroit, MI
Board Certification
- American Board of Internal Medicine - Certification in Internal Medicine
- American Board of Internal Medicine - Certification in Hematology
- American Board of Internal Medicine - Certification in Medical Oncology
Professional Memberships
- American College of Physicians
- American Society of Clinical Oncology
- Society for Immunotherapy of Cancer
Professional Experience
- 2020-2023: Attending Physician - Hematology and Medical Oncology, Infirmary Cancer Care, Mobile, AL.
Honors & Awards
- 2015 - Terry Hale Intern of the Year Award, University of Alabama School of Medicine, Montgomery Internal Medicine Residency Program
- 2015 - Best Poster Award - Clinical Vignettes, Southern Society of General Internal Medicine, New Orleans, LA.
- 2017 - Wick J. Many Award of Distinction and Excellence - Team Elite. University of Alabama School of Medicine, Montgomery Internal Medicine Residency Program
- 2016-2017: Chief Medical Resident, University of Alabama School of Medicine, Montgomery Internal Medicine Residency Program
Clinical Trials
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Learn More
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Learn More
